



# The Impact of Genetic Variants on *PTEN* Molecular Functions and Cellular Phenotypes

Nicholas Hasle,<sup>1</sup> Kenneth A. Matreyek,<sup>1</sup> and Douglas M. Fowler<sup>1,2,3</sup>

<sup>1</sup>Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA

<sup>2</sup>Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA

<sup>3</sup>Genetic Networks Program, CIFAR, Toronto, Ontario, M5G 1M1, Canada

Correspondence: dfowler@uw.edu

Phosphatase and tensin homolog (PTEN) is a tumor suppressor that directly regulates a diverse array of cellular phenotypes, including growth, migration, morphology, and genome stability. How a single protein impacts so many important cellular processes remains a fascinating question. This question has been partially resolved by the characterization of a slew of missense variants that alter or eliminate PTEN's various molecular functions, including its enzymatic activity, subcellular localization, and posttranslational modifications. Here, we review what is known about how *PTEN* variants impact molecular function and, consequently, cellular phenotype. In particular, we highlight eight informative “sentinel variants” that abrogate distinct molecular functions of PTEN. We consider two published massively parallel assays of variant effect that measured the effect of thousands of *PTEN* variants on protein abundance and enzymatic activity. Finally, we discuss how characterization of clinically ascertained variants, establishment of clinical sequencing databases, and massively parallel assays of variant effect yield complementary datasets for dissecting *PTEN*'s role in disease.

Phosphatase and tensin homolog (PTEN) is a tumor suppressor that affects cellular growth, morphology, and DNA repair (Box 1). PTEN is 403 amino acids in length and has two domains, an amino-terminal phosphatase domain and a carboxy-terminal “C2 domain” with homology to tensin, a cytoskeleton-associated protein. Following the carboxy-terminal domain, an approximately 50-residue unstructured region regulates PTEN activity. PTEN has molecular functions at the plasma membrane, cytoplasmic vesicles, and in the nucleus, including lipid phosphatase activity against phosphoinositol lipids; protein phosphatase activity against membrane-associated and nuclear pro-

teins, and enigmatic nonenzymatic functions that primarily regulate nuclear protein activity (Box 1; Table 1).

Genetic variation in *PTEN* causes human disease. *PTEN* is either somatically mutated or deleted in ~9% of all cancers. Germline *PTEN* variation causes PTEN hamartoma syndrome (PHTS), which is broadly characterized by macrocephaly, benign growths called hamartomas, and an increased risk of malignancy (Marsh et al. 1999; Yehia et al. 2019). Interestingly, many individuals with PHTS also have developmental delay and/or autism spectrum disorder, suggesting that *PTEN* also plays important roles in neurodevelopment (Butler et al. 2005). The

---

Editors: Charis Eng, Joanne Ngeow, and Vuk Stambolic

Additional Perspectives on The PTEN Family available at [www.perspectivesinmedicine.org](http://www.perspectivesinmedicine.org)

Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a036228

Cite this article as *Cold Spring Harb Perspect Med* 2019;9:a036228

### BOX 1. PTEN MOLECULAR FUNCTIONS AND THE CELLULAR PHENOTYPES THEY IMPACT

PTEN has both enzymatic and nonenzymatic molecular functions, acting as a lipid phosphatase, a protein phosphatase, and a protein scaffold. These molecular functions mediate PTEN's effects on cell growth, morphology, migration, genome stability, and DNA repair. PTEN's principal molecular function is as a phosphatase. The amino-terminal domain contains a HCXXGXXR phosphatase catalytic motif, which is capable of dephosphorylating both lipid and protein substrates (Myers et al. 1997). The primary lipid target of PTEN is phosphoinositide-(3,4,5) phosphate (PIP3), an allosteric activator of the pro-growth and pro-survival Akt/PKB pathway (Myers et al. 1998). PTEN's protein phosphatase activity shows broad target specificity, including (1) membrane associated proteins, such as focal adhesion kinase (FAK) (Tamura et al. 1998) and protein tyrosine kinase 6 (PTK6) (Wozniak et al. 2017); (2) nuclear proteins, such as cyclic AMP response element-binding protein (CREB) (Gu et al. 2011); and (3) mitotic spindle-associated proteins, such as EG5 (He et al. 2016).

PTEN also has nonenzymatic molecular functions that involve direct interaction with and modulation of downstream protein effectors in the nucleus. Two clear examples of such scaffolding activity have been reported. For example, PTEN's interaction with the anaphase-promoting complex, APC/C, increases its ubiquitination of various cell-cycle effectors (Song et al. 2011). Furthermore, PTEN interacts with RPA1 via its amino-terminal phosphatase domain and promotes RPA1 protein stability via recruitment of OTUB1 to collapsed replication forks (Wang et al. 2015). Finally, PTEN's carboxy-terminal unstructured region interacts with and inhibits PREX2, a guanine-exchange factor that activates cell migration (Mense et al. 2015).

PTEN's diverse array of molecular targets and interactions is matched by its effects on many cellular phenotypes. PTEN knockout is associated with a number of cancer hallmarks, including uncontrolled cell growth, increased tissue invasion, and genome instability. The mechanisms behind each of these cellular phenotypes are multifaceted. For example, PTEN inhibits cell growth by decreasing Akt/PKB signaling (Myers et al. 1998), by suppressing CREB transcriptional activation (Gu et al. 2011), and by promoting APC/C complex activity (Song et al. 2011). It suppresses invasion by dephosphorylating FAK, PTK6, and perhaps an unidentified lipid substrate; and by interacting with PREX2 (Tamura et al. 1998; Tibarewal et al. 2012; Mense et al. 2015; Wozniak et al. 2017). Finally, PTEN promotes DNA repair by stabilizing RPA1 and inducing FANC-mediated DNA repair at collapsed replication forks, among other uncharacterized mechanisms (Bassi et al. 2013; Wang et al. 2015; Vuono et al. 2016).

relationships between *PTEN* sequence, molecular function, structure, impact on cellular phenotype, and these clinical outcomes are only partly understood. As such, it is challenging to predict the effect of most clinically observed *PTEN* variants on somatic cancer progression or on the outcomes of patients carrying germline *PTEN* variants.

Studies of *PTEN* missense variants have helped resolve the relationships between molecular function and cellular phenotypes, as the resulting *PTEN* mutant proteins can lack individual molecular functions. Such separation-of-function variants specifically alter or abrogate some protein function while preserving others. Comparing the molecular and cellular effects of separation-of-function variants can reveal how

particular protein domains, surface pockets, and residues map to molecular functions and cellular phenotypes. Indeed, for the past 20 years, biologists have leveraged such missense variants to help dissect *PTEN*'s functionality.

Here, we review the impact of missense variants on *PTEN*'s molecular functions and cellular phenotypes. We identify eight separation-of-function "sentinel variants" that affect *PTEN*'s enzymatic activities, subcellular localization, and posttranslational modifications. We also discuss what each variant has revealed about the connections between *PTEN* molecular functions and their effects on cellular phenotype. We discuss how multiplex assays of variant effects (MAVEs) are permitting the dissection of *PTEN* variant functionality in a comprehensive man-

ner. Finally, we examine how clinical sequencing and variant characterization have shed light on the relationships between *PTEN*'s molecular functions and human disease, and we highlight clinically observed missense variants that merit further study.

### ***PTEN* VARIANTS THAT AFFECT ENZYMATIC ACTIVITY**

Shortly after *PTEN*'s discovery as a tumor suppressor, variants affecting *PTEN*'s phosphatase catalytic motif were noted in human cancers and in patients with PHTS (Li et al. 1997; Liaw et al. 1997; Marsh et al. 1999). These observations implied that *PTEN*'s phosphatase activity is important for its tumor suppressor function. However, *PTEN* has many potential phosphatase substrates, including the lipid substrate phosphoinositide-(3,4,5) phosphate (PIP3), which antagonizes the progrowth Akt/PKB pathway (Myers et al. 1998), as well as diverse protein substrates such as CREB (Gu et al. 2011), FAK (Tamura et al. 1998; Hu et al. 2014; Zhang et al. 2014), and PTK6 (Wozniak et al. 2017). To better understand which substrates are important for *PTEN*'s tumor suppressive capability, *PTEN* mutants that abrogate specific catalytic functions were characterized (Myers et al. 1998; Davidson et al. 2010). Three such mutants are of particular interest: G129E, Y138L, and C124S. These mutants selectively abrogate *PTEN* lipid

phosphatase activity, protein phosphatase activity, or both activities, respectively (Table 2).

Experiments with G129E, Y138L, and C124S revealed that *PTEN*'s lipid phosphatase activity is critical for suppression of cell growth. This conclusion is based on three distinct assays for *PTEN* lipid phosphatase activity: in vitro activity against PIP3, in vivo assessment of PIP3 levels, and in vivo assessment of phospho-AKT/PKB levels. Wild-type *PTEN* and the Y138L mutant, which both possess lipid phosphatase activity in vitro, suppressed phospho-AKT/PKB levels and cellular growth in cell culture models (Davidson et al. 2010). However, the G129E and C124S mutants, which lack in vitro PIP3 phosphatase activity, did not suppress PIP3 levels in vivo or inhibit cell growth (Myers et al. 1998; Stambolic et al. 1998). Thus, *PTEN* hydrolysis of PIP3 leads to inhibition of the progrowth PI3K-AKT/PKB pathway because PIP3 is an allosteric activator of PI3K. Importantly, subsequent work revealed that stable mutants without lipid phosphatase activity can also dimerize with and suppress the lipid phosphatase activity of wild-type alleles in a dominant negative manner (Papa et al. 2014).

Although loss of *PTEN* protein phosphatase activity does not affect cell growth, further studies of cells expressing the G129E mutant revealed that it can regulate cellular morphology and migration. For example, expression of this protein-phosphatase competent mutant inhib-



**Table 1.** *PTEN* molecular functions and impacted cellular phenotypes

| Molecular function         | Molecular target(s) | Cellular phenotype  | References   |
|----------------------------|---------------------|---|--|
| Lipid phosphatase          | PIP3                | ↓ Cell growth and survival<br>↓ Migration<br>↓ Cell spreading | Myers et al. 1998; Davidson et al. 2010; Tibarewal et al. 2012 |
| Protein phosphatase        | PTK6, FAK           | ↓ Migration<br>↓ Cell spreading                               | Tamura et al. 1998; Wozniak et al. 2017                        |
|                            | CREB                | ↓ Transcription of growth-related genes                       | Gu et al. 2011   |
|                            | FANC proteins?      | ↑ DNA repair  | Bassi et al. 2013; Vuono et al. 2016                           |
| Nonenzymatic (scaffolding) | APC/C               | ↑ Delay of G1-S transition                                    | Song et al. 2011   |
|                            | PREX2               | ↓ Migration   | Mense et al. 2015  |
|                            | RPA1, OTUB1         | ↑ RPA1-mediated resolution of stalled replication forks       | Wang et al. 2015   |

**Table 2.** Separation of enzymatic function variants

| Variant            | Lipid phosphatase activity in vitro | PKB suppression in vivo | Protein phosphatase activity | Cell growth inhibition | Migration suppression | DNA repair <sup>a</sup> | References  |
|--------------------|-------------------------------------|-------------------------|------------------------------|------------------------|-----------------------|-------------------------|---|
| Wild-type          | +                                   | +                       | +                            | +                      | +                     | +                       | Myers et al. 1998; Gildea et al. 2004; Davidson et al. 2010; Bassi et al. 2013; Vuono et al. 2016 |
| Y138L <sup>b</sup> | +                                   | +                       | -                            | +                      | +/-                   | -                       | Davidson et al. 2010; Tibarewal et al. 2012; Vuono et al. 2016                                    |
| G129E <sup>b</sup> | -                                   | -                       | +                            | -                      | +/-                   | +                       | Myers et al. 1998; Gildea et al. 2004; Davidson et al. 2010; Bassi et al. 2013; Vuono et al. 2016 |
| C124S <sup>b</sup> | -                                   | -                       | -                            | -                      | +/-                   | -                       | Myers et al. 1998; Gildea et al. 2004; Davidson et al. 2010; Bassi et al. 2013; Vuono et al. 2016 |
| Y138C              | +                                   | +                       | -                            | +                      | NS                    | NS                      | Tibarewal et al. 2012   |
| M134L              | -                                   | -                       | +                            | -                      | NS                    | NS                      | Myers et al. 1998; Han et al. 2000  |

Included are thermodynamically stable PTEN mutants for which both lipid and protein phosphatase activities have been measured. Wild-type, Y138L, G129E, and C124S are commonly used in PTEN studies.

NS, not studied.

<sup>a</sup>DNA repair capabilities as reported by Bassi et al. (2013) and Vuono et al. (2016).

<sup>b</sup>Sentinel variant.

ited glioblastoma cell line spreading on fibronectin (Tamura et al. 1998) and inhibited the migration and invasion of various cell lines (Gildea et al. 2004; Davidson et al. 2010; Mense et al. 2015). Mechanistically, these effects appear to be mediated by dephosphorylation and consequent inactivation of FAK and PTK6, which are kinases implicated in focal adhesion formation and invasion (Tamura et al. 1998; Zhang et al. 2014; Wozniak et al. 2017). Because G129E lacks

lipid phosphatase activity, these studies suggested that PTEN's protein phosphatase activity inhibits cell morphology and migration.

However, studies of the C124S and Y138L variants reveal that PTEN's role in controlling invasion is complex, context-dependent, and not solely dependent on its protein phosphatase activity. For example, the C124S and Y138L mutants partially suppressed invasion of breast cancer and glioblastoma cell lines, respectively (Da-



vidson et al. 2010; Tibarewal et al. 2012; Mense et al. 2015). Furthermore, Y138L prevented the spread of a glioblastoma cell line grown on collagen IV to a greater extent than G129E, indicating that the lipid phosphatase activity is more important than the protein phosphatase activity in this context (Davidson et al. 2010). These results suggest that the lipid phosphatase activity is capable of impacting the morphology and migration, perhaps by modulation of PIP3 gradients or a signaling pathway that is activated by PIP3 or a related lipid (Davidson et al. 2010). Interestingly, the *PTEN* C124S mutant also impacted breast cancer cell line migration via interaction with and inactivation of PREX2 (Mense et al. 2015). More experiments are required to fully understand the relative importance and context-dependence of the protein and lipid phosphatase activities in enacting changes to cellular shape and invasion.

Studies of *PTEN* variants have found that *PTEN*'s protein phosphatase function also promotes DNA repair. For example, enzymatically dead C124S was unable to induce a BRCA1-, 53BP1-, and RAD51-associated DNA damage response and, consequently, did not promote repair of dsDNA breaks in a cell culture model. However, the protein phosphatase competent G129E mutant could still do so (Bassi et al. 2013). Similarly, the protein phosphatase null Y138L mutant could not recruit FANC proteins to interstrand cross-links to enact DNA repair in murine fibroblasts and HeLa cells, but the G129E mutant could (Vuono et al. 2016). Thus, *PTEN*'s protein phosphatase function appears to coordinate the activity of many DNA repair-related proteins, including FANC proteins, BRCA1/2, and 53BP1, although the mechanism remains a mystery.

Some *PTEN* nuclear functions do not require any enzymatic activity at all. For example, C124S, which is enzymatically inactive, promoted rescue of stalled replication forks via interaction with RPA1 in a colon cancer cell line (Wang et al. 2015). This "scaffolding function" was also noted by Song and colleagues, who reported that C124S was still able to delay the G<sub>1</sub>-S transition by interacting with APC/C in murine fibroblasts and cancer cell lines (Song

et al. 2011). Thus, *PTEN* appears to function as a protein phosphatase and a protein scaffold as it fulfills its diverse nuclear roles. The role of the lipid phosphatase in the nucleus merits further study, perhaps by assaying the Y138L variant for its effects on *PTEN*'s nuclear functions.

The studies of *PTEN* function highlighted here mostly compared the effects of one or two *PTEN* variants to wild-type. To better understand how enzyme activity affects function, future studies might benefit from including at least three variants: C124S (enzymatically null), G129E (lipid-phosphatase null), and Y138L (protein-phosphatase null). We recommend inclusion of these three variants because *PTEN*-related cellular phenotypes can depend on just one activity (e.g., AKT/PKB-mediated cell growth), neither (e.g., G<sub>1</sub>-S transition), or both (e.g., cell migration; Table 2). One area of particular confusion is cellular migration and invasion, in which different conclusions have been drawn regarding the relative importance of each phosphatase activity (Gildea et al. 2004; Davidson et al. 2010; Tibarewal et al. 2012; Mense et al. 2015). These conflicts may result from differences in cell line or assay conditions, and additional studies that investigate the context-dependence of *PTEN* enzyme activity on cell migration are needed.

### ***PTEN* VARIANTS THAT AFFECT SUBCELLULAR LOCALIZATION**

The subcellular localization of *PTEN* controls its access to lipid and protein substrates. PIP3 and at least two of *PTEN*'s protein phosphatase targets, FAK and PTK6, are localized to the plasma membrane (Schaller et al. 1992; Ie Kim and Lee 2009). Furthermore, *PTEN* interacts with and dephosphorylates protein targets in the nucleus. Reflecting the importance of *PTEN* localization on its molecular functions, investigators have found and characterized variants that preclude *PTEN* localization to the plasma membrane and nuclear compartments. These variants have helped reveal the relationships between *PTEN*'s subcellular distribution and its impact on cellular phenotypes.




PTEN associates spontaneously with membranes without requiring protein–protein interactions or posttranslational modification with lipid moieties. The crystal structure of PTEN revealed a number of hydrophobic and basic regions that are likely involved in membrane binding (Fig. 1). These regions are located on the active-site face of PTEN, which presumably must interact directly with the membrane to access its lipid substrate. The membrane binding regions include the CBR3 loop (positions 263–269), the  $\alpha 2$  element (positions 327–335), the WPD loop of the active site (positions 90–93), and the TI loop (positions 161–164) (Fig. 1; Lee et al. 1999). Subsequent studies based on the structure showed that mutations in these regions led to decreased membrane binding in vitro, in a slime mold model, and in cell culture (Das et al. 2003; Nguyen et al. 2014b, 2015).

Additional mutagenesis studies revealed new residues necessary for lipid substrate binding and verified that loss of PTEN membrane localization results in loss-of-growth inhibition. For example, mutation of four amino-terminal basic residues to alanine resulted in a 76-fold decrease in PTEN's affinity for lipid vesicles in vitro and decreased plasma membrane localization in cell

culture (Das et al. 2003). Two individual mutations affecting these positions, R14A and R15A, were subsequently found to decrease PTEN membrane localization in cell culture and severely reduce its in vitro lipid phosphatase activity (Han et al. 2000; Nguyen 2014b). Interestingly, some cancer-associated mutations in the amino terminus (e.g., S10N) and the phosphatase domain (e.g., G20E, L42R, F90S) yielded competent PIP3 phosphatases in vitro but compromised membrane localization and Akt/PKB pathway inhibition in cells (Table 3; Han et al. 2000; Nguyen et al. 2015). This suggests that the in vitro PIP3 phosphatase assay will not reflect phosphatase activity in vivo if the PTEN mutant cannot localize to the membrane.

Membrane-binding defective PTEN mutants also lose access to membrane-localized protein substrates. Nguyen and colleagues showed that the cancer-associated, lipid-binding defective S10N, G20E, L42R, and F90S mutants also lost the ability to suppress breast cancer cell transwell migration (Nguyen et al. 2015). Two of PTEN's protein phosphatase targets thought to be involved in cell migration, FAK and PTK6, are membrane localized, potentially explaining this observation (Schaller et al. 1992; Ie Kim and Lee 2009). Notably, S10N, G20E, and F90S (but not L42R) also caused increased nuclear localization in a slime-mold model (Nguyen et al. 2015). However, the effect of these mutants on DNA repair and chromosome stability has not been evaluated and merits further study.

In addition to the numerous regions that drive PTEN membrane localization, there appears to be a region important for maintaining wild-type levels of PTEN in the cytoplasm. Mutants of positions 19–25 were found in tumors and result in constitutive PTEN nuclear localization in HEK293Ts. One of these mutants, F21A, showed wild-type-like lipid phosphatase activity in vitro, but lost almost all lipid phosphatase activity in vivo, as measured by AKT/PKB signaling and glioblastoma cell line growth (Denning et al. 2007). Importantly, how these variants cause nuclear localization is unknown; positions 19–25 may constitute a noncanonical nuclear export sequence, or the mechanism might in-



**Figure 1.** PTEN residues that affect subcellular localization. PTEN (PDB: 1D5R) interfaces with the membrane at the top of the structure. Residues colored in red are necessary for membrane binding and localization. Mutation of the blue residues result in increased nuclear localization. CLS, cytoplasmic localization sequence (Denning et al. 2007). (Structure from Lee et al. 1999.)

**Table 3.** Separation of localization function variants

| Variant           | Lipid phosphatase activity in vitro | PKB suppression in vivo | Membrane localization | Cytoplasmic localization | Nuclear localization | References                          |
|-------------------|-------------------------------------|-------------------------|-----------------------|--------------------------|----------------------|-------------------------------------|
| Wild-type         | +                                   | +                       | +                     | +                        | +                    | Myers et al. 1998; Das et al. 2003  |
| L42R <sup>a</sup> | +                                   | -                       | -                     | +                        | +                    | Han et al. 2000; Nguyen et al. 2015 |
| F21A <sup>a</sup> | +                                   | -                       | -                     | -                        | ++                   | Denning et al. 2007                 |
| S10N              | +                                   | -                       | -                     | +                        | ++                   | Han et al. 2000; Nguyen et al. 2015 |
| G20E              | +                                   | -                       | -                     | +                        | ++                   | Han et al. 2000; Nguyen et al. 2015 |
| F90S              | NS                                  | -                       | -                     | +                        | ++                   | Han et al. 2000; Nguyen et al. 2015 |
| R14A              | NS                                  | NS                      | -                     | +                        | NS                   | Nguyen et al. 2015                  |
| R15A              | NS                                  | NS                      | -                     | +                        | NS                   | Nguyen et al. 2015                  |

NS, not studied.

<sup>a</sup>Sentinel variant.

involve increased ubiquitination, sumoylation, and/or tyrosine phosphorylation. Furthermore, the effects of these nuclear-localized mutants on cellular migration and DNA repair is unclear.


For future studies of *PTEN*'s effects on cell biology, we recommend including the cancer-associated, membrane-binding defective L42R and nuclear-localized F21A mutants. These mutants appear to be stable, show lipid phosphatase activity in vitro, and are not known to affect posttranslational modification. Thus, these separation-of-function variants appear to modulate *PTEN*'s localization rather than its catalytic activity. As such, the downstream effects of *PTEN*'s dissociation from the membrane and constitutive localization to the nucleus can be studied by comparing the phenotypes of cells expressing the L42R and F21A sentinel variants to wild-type *PTEN*.

#### ***PTEN* VARIANTS THAT AFFECT POSTTRANSLATIONAL MODIFICATIONS**

The L42R and F21A variants discussed above appear to affect localization of *PTEN* in a constitutive manner. However, *PTEN* is also

subject to dynamic regulation of its localization by posttranslational modifications (PTMs), including serine/threonine phosphorylation, tyrosine phosphorylation, ubiquitination, and sumoylation (Fig. 2). These PTMs regulate *PTEN* stability and activity in addition to localization, and they may perform additional roles such as regulating protein-protein interactions. *PTEN* missense variants that preclude posttranslational modification have helped reveal the molecular and cellular consequences of *PTEN* regulation by PTMs (Table 4).

*PTEN*'s activity, membrane localization, and stability are all regulated by phosphorylation of its carboxy-terminal tail. Glycogen synthase kinase 3 $\beta$  and casein kinase were found to be responsible for these phosphorylation events (Torres and Pulido 2001; Al-Khoury et al. 2005), which in cell culture models resulted in a closed conformational state that could not bind the membrane, showed increased stability, and did not have lipid phosphatase activity (Vazquez et al. 2000; Das et al. 2003; Odriozola et al. 2007; Rahdar et al. 2009). Mutation of two of these phosphorylated residues to alanine (T366A/S370A) increased *PTEN*-mediated



**Figure 2.** PTEN posttranslational modifications. Ub, ubiquitination; Su, sumoylation; P, phosphorylation; Px2, Px4, residues that are cophosphorylated (Vazquez et al. 2000; Al-Khoury et al. 2005).

inhibition of AKT/PKB signaling in Jurkat cells, presumably by preventing this inactive conformational state (Al-Khoury et al. 2005). Concordantly, a second set of phosphorylation sites between residues 380 and 385 was identified, and mutation of four serine and threonine residues within this region to alanine (the “A4” variant) increased plasma membrane localization, increased *in vivo* lipid phosphatase activity, and reduced steady state PTEN abundance in various cell lines (Vazquez et al. 2000; Das et al. 2003; Rahdar et al. 2009; Nguyen et al. 2014b). Interestingly, PTEN may dephosphorylate itself at position 383, opening its conformation and permitting its interaction with and inhibition of invasion-promoting PREX2 (Raf-topoulou et al. 2004; Zhang et al. 2012; Mense et al. 2015).

PTEN is also regulated by tyrosine phosphorylation of its C2 domain, where both SRC- and PDGFR-family kinases phosphorylate PTEN on residues Y240 and Y315 (Koul et al. 2002; Nathanson et al. 2012). Y240F or Y315F mutants isolated from U251 glioma cells showed lower lipid phosphatase activity *in vitro*, suggesting that tyrosine phosphorylation is required for wild-type activity (Koul et al. 2002). However, loss of Y240 phosphorylation comes at a cost for cancer cells: this PTM was required for PTEN’s role in DNA damage repair, and cells expressing Y240F were more sensitive to DNA damaging agents than their wild-type counterparts (Ma et al. 2019). Consistent with these findings, the majority of nuclear-localized

PTEN, which carries out PTEN’s DNA repair promoting functions, were phosphorylated at Y240. Furthermore, ionizing radiation increased both the degree of PTEN Y240 phosphorylation and the amount of nuclear PTEN in glioma cell lines (Ma et al. 2019). These studies suggested that Y240/Y315 phosphorylation of PTEN is important in shifting its localization and activity from the cytoplasm to the nucleus.

Like phosphorylation, PTEN sumoylation has been implicated in regulation of PTEN localization, with critical consequences for PTEN activity at the plasma membrane and in the nucleus. PTEN was found to be sumoylated on residues K254 and K266, and mutation of these residues to sumoylation-incompetent arginine decreased membrane localization, decreased lipid phosphatase activity, and increased anchorage-dependent growth of an osteosarcoma line, compared with wild-type PTEN (Huang et al. 2012). Indeed, molecular dynamics simulations suggested that sumoylation improves membrane localization via SUMO1-mediated electrostatic interactions with the lipid bilayer (Huang et al. 2012). The K254R mutant has additional defects: decreased nuclear localization in HEK293T cells and lower DNA repair induction after DNA damage in various cell lines, compared with wild-type (Bassi et al. 2013; Vuono et al. 2016). Like tyrosine phosphorylation, loss of sumoylation can result in both lipid-phosphatase and DNA repair defects.

Ubiquitination is a third PTM that regulates PTEN localization and function. Ubiquitinated



**Table 4.** Separation of function variants that affect posttranslational modifications

| Variant            | Modification defects | Localization changes   | Steady-state abundance | Lipid phosphatase activity                             | Impacted cellular phenotypes | References   |
|--------------------|----------------------|------------------------|------------------------|--|------------------------------|--|
| K289E <sup>a</sup> | Ø ubiquitination     | ↓ Nucleus              | Normal                 | Normal   | ↓ G1/S transition delay      | Han et al. 2000; Trotman et al. 2007; Song et al. 2011; Matreyek et al. 2018       |
| K254R <sup>a</sup> | Ø sumoylation        | ↓ Nucleus              | Normal                 | ↓  | ↓ DNA damage repair          | Huang et al. 2012; Bassi et al. 2013; Vuono et al. 2016; Matreyek et al. 2018      |
| Y240F <sup>a</sup> | Ø phosphorylation    | ↓ Nucleus              | Normal                 | ↓ Koul et al. (2002)<br>Normal Nathanson et al. (2012) | ↓ DNA damage repair          | Koul et al. 2002; Nathanson et al. 2012; Matreyek et al. 2018; Ma et al. 2019      |
| T366A/S370A        | Ø phosphorylation    | None reported          | ↓                      | ↑  | ↓ Cell growth                | Vazquez et al. 2000; Al-Khoury et al. 2005; Odrizola et al. 2007                   |
| A4 <sup>b</sup>    | Ø phosphorylation    | ↓ Plasma membrane      | ↓                      | ↑  | ↓ Cell growth                | Vazquez et al. 2000, 2006; Das et al. 2003; Rahdar et al. 2009; Nguyen et al. 2015 |
| K266R              | Ø sumoylation        | ↑ Nucleus<br>↓ Nucleus | Normal                 | ↓↓   | NS                           | Huang et al. 2012  |

NS, not studied.

<sup>a</sup>Sentinel variant.<sup>b</sup>A4, S380A/T382A/T383A/S385A.

PTEN was discovered after gastrointestinal polyp biopsy of a PHTS patient carrying a germline K289E variant showed loss of nuclear PTEN. Characterization of this residue revealed that it is ubiquitinated by NEDD4-1, a membrane-localized ubiquitin ligase, and that loss of mono-ubiquitination in K289E resulted decreased of PTEN nuclear import (Trotman et al. 2007). Residue K13 was also found to be ubiquitinated and excluded from the nucleus in 293 cells if mutated to glutamate (Trotman et al. 2007; Wang et al. 2007). Furthermore, both mutants had a decreased capacity to delay the G<sub>1</sub>-S transition in PC-3 cells under normal growth conditions caused by an inability to interact with the nucleus-localized, tumor-suppressive APC/C complex (Song et al. 2011). NEDD4-1 could also polyubiquitinate PTEN at K289 and K13, and perhaps other sites, which led to protein degradation (Trotman et al. 2007). Polyubiquitination occurs less frequently than monoubiquitination for wild-type PTEN, but increased concentrations of NEDD4-1 or PTEN mutants missing the carboxy-terminal tail increased the degree of NEDD4-1 polyubiquitination and led to PTEN degradation (Wang et al. 2007). Thus, like tyrosine phosphorylation and sumoylation, ubiquitination affects the nuclear functions of PTEN. Additionally, ubiquitination is an important determinant of PTEN stability.

In conclusion, mutagenesis studies have revealed that PTEN PTMs can change the localization, enzymatic targets, or stability of PTEN, either individually or simultaneously. For example, loss of serine/threonine phosphorylation at residues 380–385 in the A4 variant decreases stability, increases membrane localization, and increases lipid phosphatase activity of PTEN. One outstanding question is how various PTMs cross talk with each other, particularly in relation to PTEN's nuclear localization, interaction with APC/C, and induction of DNA repair. Y240F (tyrosine phosphorylation-deficient), K254R (sumoylation-deficient), and K289E (ubiquitination-deficient) all appear to result in loss of nuclear PTEN. Is this because all three modified residues are necessary for nuclear localization? If so, are all nuclear functions of PTEN defective in each of these mutants?

Furthermore, the protein phosphatase activity and the effects of these mutants on migration have not been tested. More studies involving these three mutants will be required to better understand the relationships between PTEN PTMs, PTEN-induced DNA repair, and PTEN–APC/C interactions.

### USING HIGH-THROUGHPUT MUTAGENESIS TO CHARACTERIZE *PTEN* VARIANTS

The traditional biochemical and cellular experiments described above have each focused on a handful of *PTEN* variants for a subset of activities. Unfortunately, assay conditions for these one-at-a-time approaches often differ between laboratories, which restricts the ability to compare variants directly, and performing them on more than several variants is laborious. MAVEs are powerful tools for comprehensively determining how changes to protein sequence affect protein function, which can be correlated with cell and disease phenotypes (Gasperini et al. 2016; Starita et al. 2017). MAVEs enable the simultaneous assessment of thousands of genetic variants in a single experiment. Recently, MAVEs were used to assess two complementary properties of PTEN: lipid phosphatase function within yeast (Mighell et al. 2018) and intracellular abundance in human-derived cell lines (Matreyek et al. 2018). By testing thousands of possible *PTEN* missense variants, these studies yielded new insights into the relationship between PTEN's sequence, structure, and function.

Mighell et al. adapted a humanized yeast model to assess PTEN lipid phosphatase activity at high throughput (Mighell et al. 2018). Expression of the human PI3K catalytic subunit p110 inhibits yeast cell proliferation, which can be rescued by the phosphatase activity of human PTEN (Rodríguez-Escudero et al. 2005). This assay was previously used to functionally characterize dozens of *PTEN* variants (Andrés-Pons et al. 2007; Rodríguez-Escudero et al. 2011). Mighell et al. incorporated a site-saturation mutagenesis library of *PTEN* into yeast and used high-throughput sequencing to measure the

growth effects of each variant in the library in parallel. Of the 6564 missense variants that were scored with high confidence, 1789 variants showed activities below the range of scores observed for synonymous variants. Of these, 1249 had extremely low activities similar nonsense variants, with the remaining 540 variants showing an intermediate phenotype.

We developed variant abundance by massively parallel sequencing, or VAMP-seq (Matreyek et al. 2018), by fusing a library of *PTEN* single missense variants to EGFP. We used this assay to assess how each fused *PTEN* mutant altered EGFP levels and thus *PTEN* abundance. We assessed 4112 single-amino-acid mutants of *PTEN*, identifying 1138 mutants with clear loss of intracellular abundance. Thermodynamic stability appeared to be a major correlate for *PTEN* intracellular abundance, as a large subset of loss-of-abundance variants perturbed hydrophobic residues present within the core regions of each domain or at residues making hydrogen bonds in the *PTEN* crystal structure.

The results of these MAVEs are consistent with previous literature. For example, many variants altering *PTEN*'s catalytic motif caused loss of lipid phosphatase activity in the yeast functional assay, but no change in steady state abundance. Variants abrogating serine/threonine phosphorylated sites in the carboxy-terminal tail, such as S385A, showed increased activity and reduced abundance, as expected. Nonetheless, these MAVEs also come with some caveats; for example, the K254R and K266R sumoylation-defective variants do not show reduced lipid phosphatase activity in the yeast assay, as would be expected. This may be because of the lack of a *PTEN* sumoylase ortholog in yeast.

MAVEs provide a comprehensive and nuanced understanding of how *PTEN* variants affect its molecular functions. For example, not all changes to the catalytic loop completely abrogated lipid phosphatase function, as computational approaches might predict. Furthermore, there were many active site mutants that showed normal abundance yet were completely inactive; these may represent dominant negatives that act in a similar manner to C124S and G129E (Papa et al. 2014). As more *PTEN* MAVEs are com-

pleted, we expect that additional subtleties regarding *PTEN*'s sequence–structure–function relationships will come to light.

### FUNCTIONAL IMPACTS OF CLINICALLY OBSERVED *PTEN* VARIANTS

The analysis of clinical samples containing *PTEN* variants has helped elucidate the molecular and cellular mechanisms underlying *PTEN*-related disease. For example, when *PTEN* was discovered, variants of its catalytic motif sequence (e.g., G129R, M134L) were noted in diverse cancer types (Li et al. 1997; Liaw et al. 1997). Secondly, comparison of the germline variants associated with severe versus mild PHTS revealed that severe variants are often stable and catalytically inactive, whereas mild variants retain partial activity (Rodríguez-Escudero et al. 2011; Spinelli et al. 2015; Leslie and Longy 2016). Finally, Trotman et al. (2007) observed decreased *PTEN* nuclear localization after loss of heterozygosity in hamartomatous polyps in a patient with PHTS, which led to the discovery of the K289 ubiquitination site. These studies show that examination of uncharacterized patient variants has been and will continue to be vital for furthering our understanding of *PTEN* biology.

The application of exome and genome sequencing to human cancer and the diagnosis of genetic disorders is yielding a plethora of new clinical variant information. cBioPortal and ClinVar are databases that catalog somatic variants in cancer and germline variants in patients with PHTS, respectively (Cerami et al. 2012; Landrum et al. 2018; Mester et al. 2018). The relative prevalence of somatic *PTEN* variants in tumors and germline variants in patients with PHTS in these databases offer clues to regions of *PTEN* that have important functions. Indeed, 27% of all *PTEN* missense variants reported in the cBioPortal MSK-IMPACT cohort (Schrader et al. 2016) and 18% of *PTEN* variants in ClinVar are located in the phosphatase catalytic motif, which constitutes 2% of the *PTEN*'s length. Furthermore, the carboxy-terminal tail comprises 13% of *PTEN*'s length, but only 1.3% of the missense variants reported in cancer genomes are in the tail, consistent with the tail's

N. Hasle et al.

role in inhibiting PTEN access to PIP3 substrate at the plasma membrane (Vazquez et al. 2000; Das et al. 2003; Rahdar et al. 2009; Nguyen et al. 2014b).

Despite the use of single-variant studies that arise from clinical observation, most clinically reported variants have little functional data. Variants altering two positions, R130 and R173, show particularly high prevalence in clinical sequencing databases and have yet to be fully characterized. Arginine 130 is located within PTEN's HCXXGXXR catalytic motif and the MSK-IMPACT data shows that it comprises a staggering 65% of all missense variants in this region (Schrader et al. 2016). R130 variants are fairly stable (Spinelli et al. 2015; Matreyek et al. 2018), lack lipid phosphatase activity (Han et al. 2000; Mighell et al. 2018), and can exert dominant negative effects (Papa et al. 2014), just like G129E and C124S variants. However, these similarities do not explain why R130 variants are so much more common than C124 or G129 variants in cancer. Rather, it is likely that CpG dinucleotides, which constitute the first two dinucleotides of the R130 codon, are subject to higher mutation rates resulting from deamination. Given their high prevalence in cancers, additional work is needed to characterize the functional attributes and cellular consequences of R130 variants.

The *PTEN* codon encoding R173 is similarly susceptible to deamination mutations; such mutations constitute 8% of all somatic *PTEN* missense variants in cancer (Schrader et al. 2016) and have been repeatedly observed in patients with *PTEN* hamartoma tumor syndrome. The resulting *PTEN* mutants have reduced but not absent lipid phosphatase activity in Mighell and colleagues' yeast-based functional assay, suggesting that they have altered function. In the *PTEN* crystal structure, R173 is located in a helix with the TI-loop, an important determinant of phosphatase active site structure. This helix, and R173 in particular, also interacts with the C2 domain (Lee et al. 1999). Thus, the crystal structure suggests that R173 variants may affect the structure of the active site and/or interactions between the phosphatase and C2 domains. Indeed, a structural analysis of disease-associated

residues suggested that R173 forms part of an allosteric network that dictates *PTEN* conformation (Smith et al. 2019). However, specific functional data on R173 mutants, including their protein phosphatase activities, localization, and effects on DNA repair, are lacking.

Before the publication of *PTEN*-specific MAVEs, the biochemical consequences of most clinically ascertained variants—not just those affecting R130 and R173—in *PTEN* were unknown. Molecular functional data represents a critical evidence type for the clinical interpretation of variants and can help classify clinically ascertained variants as benign or pathogenic (Richards et al. 2015; Mester et al. 2018). We reported that PHTS-related *PTEN* pathogenic germline variants in ClinVar were enriched in low-abundance variants, with >80% of scored pathogenic variants being low or possibly low in abundance (Matreyek et al. 2018). Similarly, Mighell et al. (2018) found that 60% of known pathogenic *PTEN* variants had enzyme activity scores below the upper fifth percentile of the nonsense variant score distribution, corresponding to a positive predictive value of 98%. They also found that germline variants associated with autism spectrum disorder had hypomorphic activity scores, supporting a previous hypothesis linking *PTEN* phosphatase activity with phenotype (Leslie and Longy 2016).

Given the success of these studies in predicting pathogenicity, the ClinGen *PTEN* expert panel has provided guidelines for how to incorporate MAVE-generated data into clinical interpretation of variants (Mester et al. 2018). As *PTEN*'s lipid phosphatase activity appears to be most closely correlated with tumorigenesis, they recommend that functional assays measuring this molecular function, such as the yeast assay published by Mighell et al., provide the strongest evidence for pathogenicity. Examination of other biochemical deficits, such as loss of protein phosphatase activity, decreased abundance, or change in subcellular distribution, is also recommended to help determine whether or not a *PTEN* variant is pathogenic.

Although the two published MAVEs of *PTEN* have documented accuracy for classifying clinically ascertained germline *PTEN* variants,

**Table 5.** *PTEN* “sentinel variants”

| Variant | Biochemical deficit                                       | Effect on cellular phenotypes, compared with <i>PTEN</i> KO     |   |   |                                    |   | References |
|---------|---|---|---|---|------------------------------------|---|------------|
|         |   | Retained functionality, compared with <i>PTEN</i> KO            | Growth  | Migration   | DNA repair                         |   |            |
| C124S   | Loss of enzymatic activity (all)                          | Scaffolding functions   | - (↑ G <sub>1</sub> /S transition)              | - Davidson et al. 2010<br>- Gildea et al. 2004  | - (↑ replication fork progression) | Myers et al. 1998; Song et al. 2011; Wang et al. 2015                   |            |
| G129E   | Loss of lipid phosphatase activity                        | Protein phosphatase-related functions                           | -   | ↓↓ Mense et al. 2015<br>- Tibarewal et al. 2012<br>↓↓ Davidson et al. 2010                            | ↑                                  | Myers et al. 1998; Bassi et al. 2013                                    |            |
| Y138L   | Loss of protein phosphatase activity                      | Lipid phosphatase-related functions                             | ↓↓  | ↓↓ Gildea et al. 2004<br>↓↓ Mense et al. 2015<br>- Tibarewal et al. 2012<br>↓↓ (Davidson et al. 2010) | -                                  | Davidson et al. 2010; Tibarewal et al. 2012; Vuono et al. 2016          |            |
| L42R    | Loss of membrane binding                                  | Nonmembrane functions   | ↓   | ↓ Tibarewal et al. 2012   | NS                                 | Han et al. 2000; Nguyen et al. 2015                                     |            |
| F21A    | Loss of cytoplasmic localization                          | Nuclear functions   | -   | NS  | NS                                 | Denning et al. 2007   |            |
| Y240F   | Loss of phosphorylation, nuclear localization, DNA-repair | Cytoplasmic functions not dependent on tyrosine phosphorylation | -   | NS  | -                                  | Koul et al. 2002; Nathanson et al. 2012; Ma et al. 2019                 |            |
| K289E   | Loss of ubiquitination, nuclear localization              | Cytoplasmic functions not dependent on ubiquitination           | NS (normal lipid phosphatase activity in vitro) | NS  | NS                                 | Han et al. 2000; Trotman et al. 2007                                    |            |
| K254R   | Loss of sumoylation, nuclear localization                 | Cytoplasmic functions not dependent on sumoylation              | ↓   | NS  | -                                  | Huang et al. 2012; Bassi et al. 2013; Vuono et al. 2016; Ma et al. 2019 |            |

Sentinel variants affect an array of biochemical defects and cellular phenotypes and permit the functions of *PTEN* to be assessed in terms of its biochemical properties.

NS, not studied; -, no effect.



N. Hasle et al.

they only examine two aspects of PTEN biology: steady-state abundance and lipid phosphatase activity. PTEN's protein phosphatase activity and its effects on DNA repair, morphology, and migration may also be clinically relevant. For example, a mere 2% of the 293 missense *PTEN* missense variants in the MSK-IMPACT study, which sequenced a diverse array of cancer types, have been characterized according to their effect on DNA repair (Schrader et al. 2016). Given that DNA damaging agents are standard of care for many *PTEN*-mutant tumors, a MAVE focused on DNA repair could be of clinical use (Lin et al. 2014). MAVES for invasion and neuronal morphology could be similarly useful for predicting metastasis (Gildea et al. 2004; Bucheit et al. 2014; Cai et al. 2015) and autism spectrum disorder (Haws et al. 2014; Spinelli et al. 2015), respectively.

### CONCLUDING REMARKS

Missense variants have been critical tools for understanding the complex relationships between PTEN's amino acid sequence, molecular functions, and cellular effects. Here, we identify eight variants that offered key insights into PTEN by altering molecular functions in unique, defined ways (Table 5). Three of these variants (Y138L, G129E, and C124S) abrogate protein phosphatase activity, lipid phosphatase activity, or both activities. These enzyme activity separation-of-function variants have been shown to impact multiple cellular phenotypes, which can occur in a context dependent manner, highlighting the complexity of PTEN function. The remaining five variants appear to affect constitutive subcellular localization (L42R, F21A) or posttranslational modification (K254R, K289E, and Y240F). In contrast to the enzyme activity variants, the mechanism by which these variants affect migration and DNA repair has not been studied in detail; understanding their effects may shed light on how PTEN affects these critical cellular processes.

When studied together, separation of function variants allowed experimentalists to determine how cellular phenotypes correlate with particular PTEN enzymatic activities, subcellu-

lar distributions, or posttranslational modifications. For example, much of PTEN's role in DNA repair requires both protein phosphatase activity and nuclear localization, suggesting that PTEN's dephosphorylation of nuclear protein substrates is mechanistically critical. Use of these variants is not without caveats, however; insights based on these variants assume that each variant is deficient for a defined set of molecular functions, but none have been exhaustively characterized. Furthermore, as new PTEN molecular functions are characterized, this list will undoubtedly need to be updated.

Biochemical characterization of clinically ascertained *PTEN* variants have been critical for our understanding of PTEN's molecular functions and cellular phenotypic effects. As such, further characterization of disease associated R130 and R173 variants may yield new insights into *PTEN*'s role in disease. Looking forward, the prevalence of missense variants in sequencing databases will be a valuable source of information to combine with high-throughput variant characterization. By expanding the repertoire of *PTEN* MAVES, dissection of PTEN along its many axes of function will become possible. In turn, these datasets will hopefully resolve many variants of unknown significance, aid cancer risk predictions in patients with germline *PTEN* variants and help provide cancer patients with accurate prognoses and efficacious therapies.

### ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (NIH) Grants R01GM109110 (D.M.F.), F30CA236335-01 (N.H.) and the American Cancer Society Grant PF-15-221-01 (K.A.M.). D.M.F. is a CIFAR Azrieli Global Scholar.

### REFERENCES

- Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. 2005. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3 $\beta$ . *J Biol Chem* **280**: 35195–35202. doi:10.1074/jbc.M503045200



- Andrés-Pons A, Rodríguez-Escudero I, Gil A, Blanco A, Vega A, Molina M, Pulido R, Cid VJ. 2007. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. *Cancer Res* **67**: 9731–9739. doi:10.1158/0008-5472.CAN-07-1278
- Bassi C, Ho J, Srikumar T, Dowling RJO, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V. 2013. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. *Science* **341**: 395–399. doi:10.1126/science.1236188
- Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, et al. 2014. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. *Clin Cancer Res* **20**: 5527–5536. doi:10.1158/1078-0432.CCR-14-1027
- Butler MG, Dazouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, et al. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline *PTEN* tumour suppressor gene mutations. *J Med Genet* **42**: 318–321. doi:10.1136/jmg.2004.024646
- Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, Peng QX, Wu DH, Liu TF, Wang E, et al. 2015. *EBV-miR-BART7-3p* promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. *Oncogene* **34**: 2156–2166. doi:10.1038/onc.2014.341
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. 2012. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov* **2**: 401–404. doi:10.1158/2159-8290.CD-12-0095
- Das S, Dixon JE, Cho W. 2003. Membrane-binding and activation mechanism of PTEN. *Proc Natl Acad Sci* **100**: 7491–7496. doi:10.1073/pnas.0932835100
- Davidson L, MacCario H, Perera NM, Yang X, Spinelli L, Tibarewal P, Glancy B, Gray A, Weijer CJ, Downes CP, et al. 2010. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. *Oncogene* **29**: 687–697. doi:10.1038/onc.2009.384
- Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. 2007. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. *Oncogene* **26**: 3930–3940. doi:10.1038/sj.onc.1210175
- Gasperini M, Starita L, Shendure J. 2016. The power of multiplexed functional analysis of genetic variants. *Nat Protoc* **11**: 1782–1787. doi:10.1038/nprot.2016.135
- Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D. 2004. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. *Oncogene* **23**: 6788–6797. doi:10.1038/sj.onc.1207599
- Gu T, Zhang Z, Wang J, Guo J, Shen WH, Yin Y. 2011. CREB is a novel nuclear target of PTEN phosphatase. *Cancer Res* **71**: 2821–2825. doi:10.1158/0008-5472.CAN-10-3399
- Han S-Y, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K-I, Matsuno S, Kanamaru R, Ishioka C. 2000. Functional evaluation of *PTEN* missense mutations using in vitro phosphoinositide phosphatase assay. *Cancer Res* **60**: 3147–3151.
- Haws ME, Jaramillo TC, Espinosa F, Widman AJ, Stuber GD, Sparta DR, Tye KM, Russo SJ, Parada LF, Stavarache M, et al. 2014. PTEN knockdown alters dendritic spine/protrusion morphology, not density. *J Comp Neurol* **522**: 1171–1190. doi:10.1002/cne.23488
- He J, Zhang Z, Ouyang M, Yang F, Hao H, Lamb KL, Yang J, Yin Y, Shen WH. 2016. PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis. *Nat Commun* **7**: 12355. doi:10.1038/ncomms12355
- Hu Y, Xu S, Jin W, Yi Q, Wei W. 2014. Effect of the *PTEN* gene on adhesion, invasion and metastasis of osteosarcoma cells. *Oncol Rep* **32**: 1741–1747. doi:10.3892/or.2014.3362
- Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, Liu X, Cheng J, et al. 2012. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. *Nat Commun* **3**: 911–912. doi:10.1038/ncomms1919
- Je Kim H, Lee ST. 2009. Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. *J Biochem* **146**: 133–139. doi:10.1093/jb/mvp050
- Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Yung WKA. 2002. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. *Oncogene* **21**: 2357–2364. doi:10.1038/sj.onc.1205296
- Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. 2018. ClinVar: Improving access to variant interpretations and supporting evidence. *Nucleic Acids Res* **46**: D1062–D1067. doi:10.1093/nar/gkx1153
- Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. 1999. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. *Cell* **99**: 323–334. doi:10.1016/S0092-8674(00)81663-3
- Leslie NR, Longy M. 2016. Inherited *PTEN* mutations and the prediction of phenotype. *Semin Cell Dev Biol* **52**: 30–38. doi:10.1016/j.semcdb.2016.01.030
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliareis C, Rodgers L, McCombie R, et al. 1997. *PTEN*, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* **275**: 1943–1948.
- Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, et al. 1997. Germline mutations of the *PTEN* gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* **16**: 64–67. doi:10.1038/ng0597-64
- Lin F, De Gooijer MC, Roig EM, Buil LCM, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, Van Tellingen O. 2014. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888

N. Hasle et al.

- therapy. *Clin Cancer Res* **20**: 2703–2713. doi:10.1158/1078-0432.CCR-14-0084
- Ma J, Benitez JA, Li J, Kolodner RD, Chen CC, Furnari FB, Ma J, Benitez JA, Li J, Miki S, et al. 2019. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. *Cancer Cell* **35**: 504–518.e7. doi:10.1016/j.ccell.2019.01.020
- Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, et al. 1999. *PTEN* mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. *Hum Mol Genet* **8**: 1461–1472. doi:10.1093/hmg/8.8.1461
- Matreyek KA, Starita LM, Stephany JJ, Martin B, Chiasson MA, Gray VE, Kircher M, Khechaduri A, Dines JN, Hause RJ, et al. 2018. Multiplex assessment of protein variant abundance by massively parallel sequencing. *Nat Genet* **50**: 874–882. doi:10.1038/s41588-018-0122-z
- Mense SM, Barrows D, Hodakoski C, Steinbach N, Schoenfeld D, Su W, Hopkins BD, Su T, Fine B, Hibshoosh H, et al. 2018. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. *Sci Signal* **8**: ra32. doi:10.1126/scisignal.2005840
- Mester JL, Ghosh R, Pesaran T, Huether R, Karam R, Hruska KS, Costa HA, Lachlan K, Ngeow J, Barnholtz-Sloan J, et al. 2018. Gene-specific criteria for *PTEN* variant curation: Recommendations from the ClinGen *PTEN* expert panel. *Hum Mutat* **39**: 1581–1592. doi:10.1002/humu.23636
- Mighell TL, Evans-Dutson S, O’Roak BJ. 2018. A saturation mutagenesis approach to understanding *PTEN* lipid phosphatase activity and genotype-phenotype relationships. *Am J Hum Genet* **102**: 943–955. doi:10.1016/j.ajhg.2018.03.018
- Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. *Proc Natl Acad Sci* **94**: 9052–9057. doi:10.1073/pnas.94.17.9052
- Myers MP, Pass I, Batty IH, Van Der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. 1998. The lipid phosphatase activity of *PTEN* is critical for its tumor suppressor function. *Proc Natl Acad Sci* **95**: 13513–13518. doi:10.1073/pnas.95.23.13513
- Nathanson D, Bachoo RM, Wykosky J, Fenton TR, Furnari FB, Mischel PS, Dang J, de Albuquerque C P, Tanaka K, Vandenberg SR, et al. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the *PTEN* tumor suppressor at tyrosine 240. *Proc Natl Acad Sci* **109**: 14164–14169. doi:10.1073/pnas.1211962109
- Nguyen HN, Yang JM, Afkari Y, Park BH, Sesaki H, Devreotes PN, Iijima M. 2014a. Engineering ePTEN, an enhanced *PTEN* with increased tumor suppressor activities. *Proc Natl Acad Sci* **111**: E2684–E2693. doi:10.1073/pnas.1409433111
- Nguyen HN, Afkari Y, Senoo H, Sesaki H, Devreotes PN, Iijima M. 2014b. Mechanism of human *PTEN* localization revealed by heterologous expression in *Dictyostelium*. *Oncogene* **33**: 5688–5696. doi:10.1038/onc.2013.507
- Nguyen HN, Yang JM Jr, Rahdar M, Keniry M, Swaney KF, Parsons R, Park BH, Sesaki H, Devreotes PN, Iijima M. 2015. A new class of cancer-associated *PTEN* mutations defined by membrane translocation defects. *Oncogene* **34**: 3737–3743. doi:10.1038/onc.2014.293
- Odriozola L, Singh G, Hoang T, Chan AM. 2007. Regulation of *PTEN* activity by its carboxyl-terminal autoinhibitory domain. *J Biol Chem* **282**: 23306–23315. doi:10.1074/jbc.M611240200
- Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, et al. 2014. Cancer-associated *PTEN* mutants act in a dominant-negative manner to suppress *PTEN* protein function. *Cell* **157**: 595–610. doi:10.1016/j.cell.2014.03.027
- Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. 2004. Regulation of cell migration by the C2 domain of the tumor suppressor *PTEN*. *Science* **303**: 1179–1181. doi:10.1126/science.1092089
- Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. 2009. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor *PTEN*. *Proc Natl Acad Sci* **106**: 480–485. doi:10.1073/pnas.0811212106
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. 2015. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**: 405–423. doi:10.1038/gim.2015.30
- Rodríguez-Escudero I, Roelants FM, Thorner J, Nombela C, Molina M, Cid VJ. 2005. Reconstitution of the mammalian PI3K/*PTEN*/Akt pathway in yeast. *Biochem J* **390**: 613–623. doi:10.1042/BJ20050574
- Rodríguez-Escudero I, Oliver MD, Andrés-Pons A, Molina M, Cid VJ, Pulido R. 2011. A comprehensive functional analysis of *PTEN* mutations: Implications in tumor- and autism-related syndromes. *Hum Mol Genet* **20**: 4132–4142. doi:10.1093/hmg/ddr337
- Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. 1992. pp125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. *Proc Natl Acad Sci* **89**: 5192–5196. doi:10.1073/pnas.89.11.5192
- Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, et al. 2016. Germline variants in targeted tumor sequencing using matched normal DNA. *JAMA Oncol* **2**: 104–111. doi:10.1001/jamaoncol.2015.5208
- Smith IN, Thacker S, Seyfi M, Cheng F, Eng C. 2019. Conformational dynamics and allosteric regulation landscapes of germline *PTEN* mutations associated with autism compared to those associated with cancer. *Am J Hum Genet* **104**: 861–878. doi:10.1016/j.ajhg.2019.03.009
- Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP. 2011. Nuclear *PTEN* regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. *Cell* **144**: 187–199. doi:10.1016/j.cell.2010.12.020
- Spinelli L, Black FM, Berg JN, Eickholt BJ, Leslie NR. 2015. Functionally distinct groups of inherited *PTEN* mutations





- in autism and tumour syndromes. *J Med Genet* **52**: 128–134. doi:10.1136/jmedgenet-2014-102803
- Stambolic V, Suzuki A, De la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. *Cell* **95**: 29–39.
- Starita LM, Ahituv N, Dunham MJ, Kitzman JO, Roth FP, Seelig G, Shendure J, Fowler DM. 2017. Variant interpretation: Functional assays to the rescue. *Am J Hum Genet* **101**: 315–325. doi:10.1016/j.ajhg.2017.07.014
- Tamura M, Gu J, Matsumoto K, Aota S, Parsons RE, Yamada KM. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. *Science* **280**: 1614–1617.
- Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Geoffrey J, Leslie NR, et al. 2012. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. *Sci Signal* **5**: ra18. doi:10.1126/scisignal.2002138
- Torres J, Pulido R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. *J Biol Chem* **276**: 993–998. doi:10.1074/jbc.M009134200
- Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, et al. 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. *Cell* **128**: 141–156. doi:10.1016/j.cell.2006.11.040
- Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. 2000. Phosphorylation of the PTEN tail regulates protein stability and function. *Mol Cell Biol* **20**: 5010–5018. doi:10.1128/MCB.20.14.5010-5018.2000
- Vazquez F, Matsuo S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. 2006. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. *Proc Natl Acad Sci* **103**: 3633–3638. doi:10.1073/pnas.0510570103
- Vuono EA, Mukherjee A, Vierra DA, Adroved MM, Hodson C, Deans AJ, Howlett NG. 2016. The PTEN phosphatase functions cooperatively with the Fanconi anemia proteins in DNA crosslink repair. *Sci Rep* **6**: 1–13. doi:10.1038/srep36439
- Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, et al. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. *Cell* **128**: 129–139. doi:10.1016/j.cell.2006.11.039
- Wang G, Li Y, Wang P, Liang H, Cui M, Zhu M, Guo L, Su Q, Sun Y, McNutt MA, et al. 2015. PTEN regulates RPA1 and protects DNA replication forks. *Cell Res* **25**: 1189–1204. doi:10.1038/cr.2015.115
- Wozniak DJ, Kajdacsy-Balla A, Macias V, Ball-Kell S, Zenner ML, Bie W, Tyner AL. 2017. PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer. *Nat Commun* **8**: 1508. doi:10.1038/s41467-017-01574-5
- Yehia L, Ngeow J, Eng C. 2019. PTENopathies: From biological insights to evidence-based precision medicine. *J Clin Invest* **129**: 452–464. doi:10.1172/JCI121277
- Zhang XC, Piccini A, Myers MP, Van Aelst L, Tonks NK. 2012. Functional analysis of the protein phosphatase activity of PTEN. *Biochem J* **444**: 457–464.
- Zhang LL, Liu J, Lei S, Zhang J, Zhou W, Yu HG. 2014. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. *Cell Signal* **26**: 1011–1020. doi:10.1016/j.cellsig.2014.01.025